XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of stock option activity

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Outstanding Options and RSUs

​

    

​

    

​

    

​

    

Weighted-

    

​

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

Shares

​

Number of

​

Average

​

Remaining

​

Aggregate

​

​

Available for

​

Shares

​

Exercise

​

Contractual

​

Intrinsic

(in thousands, except for contractual life and exercise price)

​

Grant

​

Outstanding

​

Price

​

Life

​

Value

​

​

​

​

​

​

​

​

​

(in years)

​

​

Balance at December 31, 2022

 

3,263

 

5,300

​

$

21.11

 

4.84

​

$

131,385

Additional shares authorized

 

3,500

​

—

​

​

​

​

​

​

​

​

Options granted

 

(317)

 

317

​

$

44.17

​

​

​

​

​

Options exercised

 

—

 

(169)

​

$

13.63

​

​

​

​

​

RSUs granted

​

(5,369)

​

—

​

​

​

​

​

​

​

​

RSUs forfeited/cancelled

​

250

​

—

​

​

​

​

​

​

​

​

Balance at March 31, 2023

 

1,327

 

5,448

​

$

22.69

​

4.93

​

$

199,854

Exercisable at March 31, 2023

​

​

 

4,541

​

$

13.25

​

4.15

​

$

194,651

Vested and expected to vest at March 31, 2023

​

​

 

5,392

​

$

22.21

​

4.89

​

$

199,545

​

Restricted stock units

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted-

​

​

​

​

Average

​

​

​

​

Grant Date

(in thousands, except for grant date fair value)

​

Shares

​

Fair Value

​

​

​

​

​

​

Balance at December 31, 2022

​

6,836

​

$

57.12

Granted

​

5,369

​

$

44.75

Vested

​

(1,599)

​

$

57.36

Cancelled/forfeited

​

(250)

​

$

51.95

Balance at March 31, 2023

​

10,356

​

$

50.75

​

Summary of stock-based compensation expenses

The following tables present the effect of employee and non-employee stock-based compensation expense on selected statements of operations line items for the three months ended March 31, 2023 and 2022.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended March 31, 

​

​

2023

​

2022

​

    

Employee

    

Non-Employee

    

Total

    

Employee

    

Non-Employee

    

Total

​

​

(in thousands)

Cost of revenues

​

$

2,554

​

$

2

​

$

2,556

​

$

1,716

​

$

—

​

$

1,716

Research and development

​

 

14,315

​

 

543

​

 

14,858

​

 

9,006

​

 

415

​

 

9,421

Selling, general and administrative

​

 

22,959

​

 

322

​

 

23,281

​

 

23,875

​

 

75

​

 

23,950

Total

​

$

39,828

​

$

867

​

$

40,695

​

$

34,597

​

$

490

​

$

35,087

​

Employee stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of assumptions used in valuation of fair value

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended March 31, 

​

    

2023

    

    

2022

    

Expected term (years)

 

5.20

​

—

6.00

​

 

5.12

​

—

10.00

​

Expected volatility

 

68.61

%

—

70.07

%

 

55.91

%

—

62.30

%

Expected dividend rate

 

​

​

​

0.00

%

 

​

​

​

0.00

%

Risk-free interest rate

 

3.41

%

—

3.58

%

 

1.62

%

—

1.78

%

​